FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 349 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer... June 10, 2026 How to Strengthen Your Immune System: Part 1 September 17, 2020 FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for HER2-Mutated NSCLC September 2, 2022 Implementation of Door-to-Door HPV-based Cervix Screening Results in Better Attendance of... April 17, 2023 Load more HOT NEWS Approximately 1 Million of New Maternal Orphans Due to Cancer in... Aspartame and cancer – sweet nothings? Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS... David Dangoor: “Education is a treasure that you give someone and...
